Abstract: Fusarinine C (FSC) has recently been shown to be a promising and novel chelator for 89 Zr. Here, FSC has been further derivatized to optimize the complexation properties of FSC-based chelators for 89 Zr-labeling by introducing additional carboxylic groups. These were expected to improve the stability of 89 Zr-complexes by saturating the 8-coordination sphere of [ 89 Zr] Zr 4+ , and also to introduce functionalities suitable for conjugation to targeting vectors such as monoclonal antibodies. For proof of concept, succinic acid derivatization at the amine groups of FSC was carried out, resulting in FSC(succ) 2 and FSC(succ) 3 . FSC(succ) 2 was further derivatized to FSC(succ) 2 AA by reacting with acetic anhydride (AA). The Zr 4+ complexation properties of these chelators were studied by reacting with ZrCl 4 . Partition coefficient, protein binding, serum stability, acid dissociation, and transchelation studies of 89 Zr-complexes were carried out in vitro and the results were compared with those for 89 
chelators for 89 Zr-labeling by introducing additional carboxylic groups. These were expected to improve the stability of 89 Zr-complexes by saturating the 8-coordination sphere of [ 89 Zr] Zr 4+ , and also to introduce functionalities suitable for conjugation to targeting vectors such as monoclonal antibodies. For proof of concept, succinic acid derivatization at the amine groups of FSC was carried out, resulting in FSC(succ) 2 and FSC(succ) 3 . FSC(succ) 2 was further derivatized to FSC(succ) 2 AA by reacting with acetic anhydride (AA). The Zr 4+ complexation properties of these chelators were studied by reacting with ZrCl 4 . Partition coefficient, protein binding, serum stability, acid dissociation, and transchelation studies of 89 Zr-complexes were carried out in vitro and the results were compared with those for 89 Zr-desferrioxamine B ([ 89 Zr]Zr-DFO) and 89 Zr-triacetylfusarinine C ([ 89 Zr]Zr-TAFC). The in vivo properties of [ 89 Zr]Zr-FSC(succ) 3 were further compared with [ 89 Zr]Zr-TAFC in BALB/c mice using micro-positron emission tomography/computer tomography (microPET/CT) imaging. Fusarinine C (succ) 2 AA and FSC(succ) 3 were synthesized with satisfactory yields. Complexation with ZrCl 4 was achieved using a simple strategy resulting in high-purity Zr-FSC(succ) 2 AA and Zr-FSC(succ) 3 with 1:1 stoichiometry. Distribution coefficients of 89 Zr-complexes revealed increased hydrophilic character compared to [ 89 Zr]Zr-TAFC. All radioligands showed high stability in phosphate buffered saline (PBS) and human serum and low protein-bound activity over a period of seven days. Acid dissociation and transchelation studies exhibited a range of in vitro stabilities following the order: [ 89 Zr]Zr-FSC(succ) 3 3 showed the best stability and inertness. The promising results obtained with [ 89 Zr]Zr-FSC(succ) 2 AA highlight the potential of FSC(succ) 2 as a monovalent chelator for conjugation to targeted biomolecules, in particular, monoclonal antibodies.
Introduction
Immuno-positron emission tomography (PET) is of great value for the development of monoclonal antibodies (mAbs) as therapeutic targeting vectors, enabling tracking and quantification of radiolabeled mAbs at high resolution and sensitivity [1] . In recent years, Zirconium-89 ( 89 Zr), in particular, has become the most commonly-studied positron-emitting radionuclide for immuno-PET imaging. The physical half-life of 78.4 h is a good match with the biological half-life of mAbs, thus increasing the utility of PET in the development of this class of compound, and its medium mean positron energy of 0.395 MeV allows high-resolution PET imaging [2] . Additionally, in contrast to iodine-124, another long-lived positron-emitter, which has a rapid release of radioiodine from the cell after internalization, 89 Zr is a residualizing radiometal and facilitates the visualization of tumors [3] . As an osteophilic radionuclide, immuno-PET imaging with 89 Zr requires stable coordination of the radionuclide with the chelator to minimize dissociation resulting in bone accumulation in vivo.
To date, desferrioxamine B (DFO), see Figure 1 , has been the most widely used bifunctional chelating system for 89 Zr-based radiopharmaceuticals. Although chelation with DFO results in complexes with acceptable stability in pre-clinical as well as some clinical studies, it is far from being optimal due to the partial release of [ 89 Zr]Zr 4+ from the chelating system [4] . The released [ 89 Zr]Zr 4+ has been reported to accumulate in bone, particularly at late time points (3-7 days), which results in a decrease in image contrast, as well as an increase in radiation dose, especially to bone marrow [5] [6] [7] [8] [9] [10] . The instability of DFO is attributed to the linear structure (which allows easy access to challenging cations and natural chelators in vivo), as well as to the incomplete saturation of the 8-coordination sphere of Zr 4+ [11] . The development of novel high-stability Zr 4+ -ligands to minimize the uptake of liberated Zr 4+ in the bone and other non-targeted tissue is an interesting and important goal. While many investigators focus on the optimization of the conjugation moiety between DFO and the biomolecule, attempts to develop new chelators are increasing [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Several novel octadentate and oxygen-rich 89 Zr-chelators have been reported showing improved in vitro stability. These novel chelators are designed to be acyclic or macrocyclic by the addition of another hydroxamate unit [12, 13, 17, 19, 21] or introduce new chelating groups such as hydroxypyridinone and pyrocatechol groups [14] [15] [16] 20 ].
To date, desferrioxamine B (DFO), see Figure 1 , has been the most widely used bifunctional chelating system for 89 Zr-based radiopharmaceuticals. Although chelation with DFO results in complexes with acceptable stability in pre-clinical as well as some clinical studies, it is far from being optimal due to the partial release of [ 89 Zr]Zr 4+ from the chelating system [4] . The released [ 89 Zr]Zr 4+ has been reported to accumulate in bone, particularly at late time points (3-7 days), which results in a decrease in image contrast, as well as an increase in radiation dose, especially to bone marrow [5] [6] [7] [8] [9] [10] . The instability of DFO is attributed to the linear structure (which allows easy access to challenging cations and natural chelators in vivo), as well as to the incomplete saturation of the 8-coordination sphere of Zr 4+ [11] . The development of novel high-stability Zr 4+ -ligands to minimize the uptake of liberated Zr 4+ in the bone and other non-targeted tissue is an interesting and important goal. While many investigators focus on the optimization of the conjugation moiety between DFO and the biomolecule, attempts to develop new chelators are increasing [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Several novel octadentate and oxygen-rich 89 Zr-chelators have been reported showing improved in vitro stability. These novel chelators are designed to be acyclic or macrocyclic by the addition of another hydroxamate unit [12, 13, 17, 19, 21] or introduce new chelating groups such as hydroxypyridinone and pyrocatechol groups [14] [15] [16] 20] . Recently, we reported that fusarinine C (FSC), which has a 36-membered ring structure and three bidentate hydroxamates to coordinate 89 Zr, showed superior stability and kinetic inertness compared to DFO. In particular, the excellent targeting properties of FSC bioconjugates in PET-imaging studies showed FSC to be a highly promising alternative chelator for 89 Zr [23] [24] [25] . However, since FSC is hexadentate rather than octadentate, we postulated that improvements could be expected by introducing additional coordinating groups to saturate the coordination sphere of [ 89 Zr]Zr 4+ . Another potential drawback of FSC as a 89 Zr-bifunctional chelator lies in it having three functionalities for derivatization, which, despite facilitating the employment of multivalent concepts for small molecules, are not suitable for conjugation to macromolecules, especially antibodies. Therefore, a further aim of this study was to design a FSC-based mono-functional 89 Zr-chelator. As proof of concept, modifications via succinic acid derivatization resulting in FSC(succ) 2 acetic anhydride (AA) and FSC(succ) 3 , see Figure 1 , were developed. This straightforward modification introduces additional carboxylic acid groups known to coordinate with Zr, which additionally can be utilized for bioconjugation strategies. In this study, the in vitro stability and transchelation properties of these 89 
Materials and Methods
All commercially available reagents were of reagent grade and used as supplied with no further purification. Desferrioxamine B was obtained from Genaxxon Bioscience GmbH (Ulm, Germany). Triacetylfusarinine C was prepared and purified as described previously [23] . [ 89 Zr]Zr-oxalate was purchased from Perkin Elmer, Inc (Waltham, MA, US) with an activity concentration of 900-1000 MBq per milliliter.
Purification of compounds was performed via a preparative reversed-phase high-performance liquid chromatography system (preparative RP-HPLC) using a Gilson 322 HPLC pump, a Gilson ultraviolet (UV)/VIS-155 detector (Gilson International B.V., Limburg, Germany), and a Eurosil Bioselect Vertex Plus 300 × 8 mm 5 µm C 18A 300 Å column (Knauer, Berlin, Germany) with a flow rate of 3.0 mL/min. The gradient was as follows: 0-1.0 min 10% acetonitrile (CH 3 CN), 1.0-18.0 min 10-40% CH 3 CN (gradient A).
Analytical RP-HPLC analysis was performed with an UltiMate 3000 RS HPLC pump, an UltiMate 3000 RS column compartment (column oven temperature was set at 25 • C), an UltiMate 3000 UV-Vis variable wavelength detector (Dionex, Gemering, Germany), and a Raytest radiometric detector (Raytest GmbH, Straubenhardt, Germany). A Vydac 218 TP5215, 150 × 3.0 mm column (SRD, Vienna, Austria), flow rate 1.0 mL/min, and UV-Vis detection at 220/410 nm were employed with the following CH 3 CN/H 2 O/0.1% trifluoroacetic acid (TFA) gradient: 0-0.5 min 0% CH 3 CN/0.1% TFA, 0.5-7.0 min, 0-55% CH 3 CN/0.1% TFA (gradient B).
Fusarinine C
Fusarinine C was produced as described previously [23] . Briefly, the Aspergillus fumigatus mutant strain ∆sidG was cultured in iron-free minimal medium with 1% glucose for 36 h at 37 • C and 200 rpm. Biomass was removed by filtration. The media-containing siderophore was collected and concentrated. Additional purification was performed via preparative RP-HPLC (gradient A, t R = 10.2 min) followed by concentration and lyophilization. Analytical RP-HPLC (gradient B): t R = 4.7 min.
Fusarinine C (succ) 3
To FSC (50 mg, 69 µmol) dissolved in 1 mL dimethylformamide (DMF), 34.5 mg of succinic anhydride (5 eq, 0.34 mmol) was added and the pH was adjusted to 4.5 using N,N-diisopropylethylamine (DIPEA). After shaking for 0.5 h, FSC(succ) 3 was directly isolated via preparative RP-HPLC (gradient A, t R = 12.1 min) and confirmed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The collected fractions were concentrated and lyophilized. FSC(succ) 3 The general synthesis procedure of FSC(succ) 2 was the same as that of FSC(succ) 3 except that a 2 eq molar excess of succinic anhydride was used. FSC(succ) 2 was isolated from the byproducts (FSC-succ and FSC(succ) 3 ) via preparative RP-HPLC (gradient A, t R = 11.5 min). FSC(succ) 2 2.5. Zr-Fusarinine C(succ) 2 AA and Zr-Fusarinine C(succ) 3 .
ZrCl 4 (121 mg) was dissolved in 1 mL 0.1 M hydrochloric acid solution resulting in a concentration of 0.52 M. After dissolving FSC(succ) 2 AA (5 mg, 5.2 µmol) or FSC(succ) 3 (5 mg, 4.9 µmol) in 1 mL water, a 1.2 eq molar excess of ZrCl 4 (11.9 µL and 11.3 µL, respectively) was added. The reaction solutions were shaken gently for 5 min, then loaded onto a pre-activated Sep-Pak C 18 cartridge. After washing the cartridge with 10 mL water, Zr-FSC(succ) 2 AA and Zr-FSC(succ) 3 were eluted with 1mL methanol. The eluate fractions were dried by evaporation under nitrogen and weighed. The identities of the products were confirmed by electrospray ionization mass spectrometry (ESI-MS). Zr-FSC(succ) 2 
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The general synthesis procedure of FSC(succ)2 was the same as that of FSC(succ)3 except that a 2 eq molar excess of succinic anhydride was used. FSC(succ)2 was isolated from the byproducts (FSCsucc and FSC ( 
Fusarinine C(succ)2AA
To FSC(succ)2 (10 mg, 11 μmol) dissolved in 0.5 mL DMF, 1 mL of acetic anhydride (AA) was added. After shaking for 10 min, FSC(succ)2AA was quickly isolated via preparative RP-HPLC (gradient A, tR = 11.9 min) and confirmed by MALDI-TOF-MS. The collected fractions were concentrated and lyophilized. FSC(succ)2AA: yield: 9 mg, (9. 
Zr-Fusarinine C(succ)2AA and Zr-Fusarinine C(succ)3.
ZrCl4 (121 mg) was dissolved in 1 mL 0.1 M hydrochloric acid solution resulting in a concentration of 0.52 M. After dissolving FSC(succ)2AA (5 mg, 5.2 μmol) or FSC(succ)3 (5 mg, 4.9 μmol) in 1 mL water, a 1.2 eq molar excess of ZrCl4 (11.9 μL and 11.3 μL, respectively) was added. The reaction solutions were shaken gently for 5 min, then loaded onto a pre-activated Sep-Pak C18 cartridge. After washing the cartridge with 10 mL water, Zr-FSC(succ)2AA and Zr-FSC(succ)3 were eluted with 1mL methanol. The eluate fractions were dried by evaporation under nitrogen and weighed. The identities of the products were confirmed by electrospray ionization mass spectrometry (ESI-MS). Zr-FSC(succ)2AA: yield: 3.6 mg, 
89 Zr-Labeling
Approximately 30 MBq (30 µL) of [ 89 Zr]Zr-oxalate was mixed with 27 µL of sodium carbonate (Na 2 CO 3 , 1 M) and incubated for 3 min at room temperature (RT) [26] . Thereafter, 100 µL of 4-(2-hydroxyethyl)-1-piperazineëthanesulfonic acid (HEPES) buffer (0.5 M, pH 7.0) was added to the reaction vial. Either DFO (32.8 µg), TAFC (42.6 µg), FSC(succ) 2 AA (48.5 µg) or FSC(succ) 3 (51.4 µg) was added to the reaction vial. The labeling mixture was allowed to react at RT with a pH between 6.8 and 7.2 for 90 min. The reaction progress was monitored via analytical RP-HPLC (gradient B 3 : t R = 6.0 min.
For animal experiments, 60 µL of CaCl 2 (0.5 M) was added to the radiolabeling solution and a precipitate of Ca-oxalate appeared. The solution was then passed through a 0.2-µm filter to remove Ca-oxalate which may cause kidney failure. Subsequently, the filtrate was diluted to an appropriate volume using saline for administration to the BALB/c mice. 3 was carried out by incubating the radioligands in PBS, a 1000-fold molar excess of ethylenediaminetetraacetic acid (EDTA) solution (radioligand vs. EDTA: 25 µM vs. 25 mM) with different pH (pH 7, pH 6, and pH 4), as well as in human serum (the human serum was obtained from author C.D. with his consent at the Medical University Innsbruck within a routine blood withdrawal procedure) for seven days at 37 • C. At selected time points, PBS and EDTA samples were analyzed in triplicate directly via analytical RP-HPLC, while serum aliquots were mixed with 500 µL of CH 3 CN, vortexed, and centrifuged at 20,000 rcf for 2 min. Then, the precipitate was washed three times using CH 3 CN before analysis. 3 for seven days at 37 • C in fresh human serum. Subsequently, 30 µL of the solution was passed through a size exclusion spin column (MicroSpinG-50 column, GE Healthcare, Buckinghamshire, UK) via centrifugation at 2000 rcf for 2 min. Protein binding of the complexes in triplicate was determined by measuring the activity on the column (non-protein bound) and the activity in the eluate (protein bound) in the gamma counter. 
In Vitro Characterization

Results
Synthesis
The straightforward synthesis of FSC(succ) 2 AA and FSC(succ) 3 is shown in Scheme 1. Fusarinine C was reacted with succinic anhydride at pH 4.5 resulting in FSC(succ) 3 and FSC(succ) 2 in satisfactory yields of 88 ± 4.0% and 43 ± 4.5%, respectively. The unreacted amine group of FSC(succ) 2 
89 Zr-Labeling
The 89 Zr-labeling procedure of DFO, TAFC, FSC(succ)2AA and FSC(succ)3 was as previously described [23] . 
Ex Vitro Characterization
Fusarinine C(succ)2AA and FSC(succ)3 showed high solubility in water, which is comparable to TAFC but different from recently reported novel octadentate chelators which seem to have poor solubility [9] Table 1 
89 Zr-Labeling
The 89 Zr-labeling procedure of DFO, TAFC, FSC(succ) 2 AA and FSC(succ) 3 was as previously described [23] . 3 along the ITLC strips.
Ex Vitro Characterization
Fusarinine C(succ) 2 AA and FSC(succ) 3 showed high solubility in water, which is comparable to TAFC but different from recently reported novel octadentate chelators which seem to have poor solubility [9] Figure 3C . 
Biodistribution Study and Micro-Positron Emission
Discussion
The high potential of FSC as a novel multivalent 89 Zr-bifunctional chelator was demonstrated by our group recently [23] . However, the six coordinating oxygens of FSC do not coordinatively saturate the Zr 4+ . In addition, three of the functionalities of FSC may limit its application to the macromolecules, especially antibodies. On this basis, we were interested in designing novel chelators based on FSC by introducing two or three carboxylic functional groups, which were expected to, on one hand, improve the stability of complexation by saturating the coordination sphere of [ 89 Zr]Zr 4+ and, on the other hand, reduce the number of conjugation groups making them suitable for conjugation to mAbs.
As proof of concept, two or three succinic acid groups were introduced into the FSC skeleton and FSC(succ)2, FSC(succ)2AA and FSC(succ)3 were synthesized with satisfactory yields. In our previous report, we discovered that iron protection is required for coupling FSC with targeting vectors [23] . However, the present study revealed that FSC can couple active groups such as anhydride groups at acidic pH, which provides a simpler conjugation approach. Moreover, the successful synthesis of FSC(succ)2 and FSC(succ)2AA opens a way to apply it to mAbs. FSC(succ)2, which has only one free amine functionality left, possesses the potential to couple mAbs with an activated group resulting in a monomeric FSC(succ)2-mAb.
In this study, the rapid and quantitative complexing of FSC(succ)2AA and FSC(succ)3 with ZrCl4 was reported and confirmed by ESI-MS. In our previous papers, we reported simple quantitative binding of ZrCl4 with TAFC at acidic pH (1-5) within 5 min [23] and quantitative labeling of TAFC 
As proof of concept, two or three succinic acid groups were introduced into the FSC skeleton and FSC(succ) 2 , FSC(succ) 2 AA and FSC(succ) 3 were synthesized with satisfactory yields. In our previous report, we discovered that iron protection is required for coupling FSC with targeting vectors [23] . However, the present study revealed that FSC can couple active groups such as anhydride groups at acidic pH, which provides a simpler conjugation approach. Moreover, the successful synthesis of FSC(succ) 2 and FSC(succ) 2 AA opens a way to apply it to mAbs. FSC(succ) 2 , which has only one free amine functionality left, possesses the potential to couple mAbs with an activated group resulting in a monomeric FSC(succ) 2 -mAb.
In this study, the rapid and quantitative complexing of FSC(succ) 2 AA and FSC(succ) 3 with ZrCl 4 was reported and confirmed by ESI-MS. In our previous papers, we reported simple quantitative binding of ZrCl 4 with TAFC at acidic pH (1-5) within 5 min [23] and quantitative labeling of TAFC with may be a better choice for labeling FSC derivatives in acetate buffer at appropriate pH. The advantage of [ 89 Zr]ZrCl 4 over 89 Zr-oxalate lies not only in the shorter labeling time but also in avoiding the use of highly concentrated oxalate solution which potentially can result in the production of solid calcium oxalate causing kidney damage. In contrast to HEPES buffer, which requires additional quality control before clinical application, acetate buffer is entirely pharmaceutically compatible. For better understanding the exact coordination structures as well as their influence on stability, the preparation of single crystals of Zr-TAFC, Zr-FSC(succ) 2 AA and Zr-FSC(succ) 3 for X-ray Diffraction was explored using different strategies; however, this failed. Multivalent hydroxamates seem not to crystallize easily, and this may be the reason that Zr(Me-AHA) 4 is the only successfully crystallized Zr-hydroxamate compound [11] .
To 3 was significantly higher than that of [ 89 Zr]Zr-TAFC, possibly mainly reflecting the slower clearance rather than being actual bone uptake. Even though different time points were chosen for an imaging study, this was confirmed by images at 24 h p.i. showing both radioligands without visible bone uptake. [ 89 Zr]Zr-FSC(succ) 3 also showed some hepatobiliary excretion in microPET/CT images at the early time point of 80 min, which was not depicted at 24 h p.i. and in the 6 h p.i. biodistribution study. The overall difference in biodistribution may be attributed to the difference in the chelate-radiometal net charge and polarity. [ 89 Zr]Zr-TAFC possesses a positive net charge while [ 89 Zr]Zr-FSC(succ) 3 shows an overall negative charge character, which may potentially influence the excretion patterns of radiotracers. However, the difference in clearance rates between [ 89 Zr]Zr-FSC(succ) 3 and [ 89 Zr]Zr-TAFC should not be a concern in its final application. Upon conjugation to a targeting biomolecule, the pharmacokinetics of the [ 89 Zr]Zr-FSC(succ) 3 complex will be completely superseded by those of biomacromolecules. Higher kidney and lower liver uptake compared to [ 89 Zr]Zr-TAFC indicates a renal excretion pathway, which is consistent with the higher hydrophilicity of [ 89 Zr]Zr-FSC(succ) 3 .
Conclusions
In our study, three FSC derivatives were synthesized and labeled with zirconium-89. 
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